SCHEDULE 13D/A: Perceptive Funds Trim Trinity Biotech Stake Amid Price Decline

Perceptive Credit Holdings II, L.P. sold nearly 2 million American Depositary Shares of Trinity Biotech plc between December 2025 and January 2026, with prices declining significantly.

Summary

• Perceptive Advisors LLC and its affiliated funds (Perceptive Credit Holdings II, L.P. and Perceptive Credit Holdings III, L.P.) collectively report beneficial ownership of 1,463,058,248 Class A Ordinary Shares of Trinity Biotech plc, representing 9.9% of the class.
• This ownership includes shares issuable from warrants (65,000,000 Ordinary Shares), a Convertible Note (1,165,048,540 Ordinary Shares), a Milestone Payment Obligation (97,087,378 Ordinary Shares), and a Contingent Payment Obligation (135,922,330 Ordinary Shares).
• The conversion price for ADSs from these obligations is based on a Floor Price of $1.03.
• A Beneficial Ownership Cap restricts the exercise and conversion of these instruments if it would cause the holder's beneficial ownership to exceed the cap.
• Perceptive Credit Holdings II, L.P. executed multiple sales of Trinity Biotech ADSs between December 23, 2025, and January 22, 2026.
• A total of 1,989,000 ADSs were sold during this period.
• Sale prices ranged from a high of $1.64 per ADS on December 23, 2025, to a low of $0.70 per ADS in mid-January 2026.

Sentiment

Score: 3

Explanation: The continuous selling of a significant number of ADSs by a major holder, coupled with a substantial decline in sale prices, indicates a negative sentiment regarding the issuer's short-term prospects or the holder's investment thesis.

Positives

• The reporting persons maintain a significant potential beneficial ownership stake of 9.9% in Trinity Biotech plc, indicating continued interest through convertible instruments.

Negatives

• Perceptive Credit Holdings II, L.P. sold a substantial number of ADSs (1,989,000) over a short period.
• The sale prices for these ADSs experienced a significant decline, from $1.64 on December 23, 2025, to as low as $0.70 by January 2026.
• The continuous selling pressure from a major holder could indicate a lack of confidence or a need for liquidity.

Risks

• The Beneficial Ownership Cap restricts the full conversion of warrants, convertible notes, and payment obligations into Ordinary Shares, potentially limiting the upside for the holders if the share price increases significantly.
• Ongoing sales by a significant beneficial owner could exert downward pressure on the stock price.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from the company or the reporting persons regarding Trinity Biotech plc's future performance or strategic direction, beyond the inherent nature of the convertible instruments.

Industry Context

This Schedule 13D/A filing primarily details changes in beneficial ownership by an investment fund and does not provide specific industry context or analysis of Trinity Biotech plc's position within its sector.

Stakeholder Impact

• Shareholders: The continuous selling by a major holder, especially at declining prices, could create downward pressure on the stock price and signal reduced confidence, potentially impacting other shareholders negatively.
• Creditors: The conversion of debt-like instruments (Convertible Note, Milestone/Contingent Payment Obligations) into equity could alter the company's capital structure, which might be viewed differently by creditors depending on the terms and overall financial health.

Key Dates

Recommendation

The consistent selling of a large block of shares by a sophisticated institutional investor, Perceptive Credit Holdings II, L.P., over a period where the share price significantly declined, suggests a negative outlook from a well-informed party. This sustained selling pressure, coupled with the declining prices, indicates potential underlying issues or a lack of confidence in the company's near-term performance. Investors should consider this as a strong signal to reduce or exit their positions, as further selling could continue to depress the stock price.

Keywords

Trinity Biotech, Perceptive Advisors, Schedule 13D/A, Beneficial Ownership, ADS, Ordinary Shares, Convertible Note, Warrants, Milestone Payment Obligation, Contingent Payment Obligation, SEC Filing, Stock Sales